Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences CFO & Treasurer Kevin Tan reported multiple equity transactions. On January 29, 2026, 56,646 performance stock units converted one-for-one into common stock, increasing his directly held common shares to 102,746. That same day he received an employee stock option for 187,000 shares vesting over four years and a new grant of 93,500 restricted stock units, also vesting over four years.
On January 31, 2026, 33,075 restricted stock units from a prior 2025 grant vested and converted into common stock, lifting his direct holdings to 135,821 shares. On February 2, 2026, he sold 26,837 shares at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-arranged automatic sell-to-cover instruction, leaving 108,984 common shares held directly.
Solid Biosciences Inc.’s President and CEO Alexander Cumbo reported multiple equity compensation events and a tax-related share sale. On January 29, 2026, 169,401 performance stock units vested into common shares, he received an option grant for 509,850 shares at $6.60, and was granted 254,900 RSUs.
On January 31, 2026, 100,400 RSUs from a prior grant vested into common stock. On February 2, 2026, Cumbo sold 80,258 shares at a weighted average price of $6.4369 to cover withholding taxes under an automatic sell-to-cover instruction, leaving him with 270,931 directly held common shares plus unvested RSUs and options.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported equity vesting, new grants, and a tax-related share sale. On January 29, 2026, 54,925 performance stock units converted into common stock and 190,000 employee stock options plus 95,000 restricted stock units were granted.
On January 31, 2026, 27,625 restricted stock units vested into common shares. On February 2, 2026, 26,535 common shares were sold at a weighted average price of $6.4369 to cover withholding taxes under a pre-established automatic sell-to-cover instruction, leaving 82,675 common shares held directly.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported multiple equity compensation events and a related stock sale. On January 29, 2026, 58,847 performance stock units vested into common stock after a performance milestone was certified as achieved, increasing his holdings before later transactions.
That same day, he received an option to buy 207,450 shares at an exercise price of $6.60 per share, vesting over four years, and 103,750 restricted stock units that also vest over four years in 25% annual installments. On January 31, 2026, 28,225 restricted stock units from a 2025 grant vested into common stock.
On February 2, 2026, Brooks sold 28,335 shares of common stock at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting under a pre-arranged automatic sell-to-cover instruction. Following these transactions, he directly held 96,708 shares of Solid Biosciences common stock.
Solid Biosciences’ Chief Operating Officer David Howton reported multiple equity compensation events and a related share sale. On January 29, 2026, 79,341 performance stock units vested and converted into common stock, and he received 105,100 new restricted stock units plus an option for 210,200 shares at an exercise price of $6.60 per share, all vesting over four years.
On January 31, 2026, an additional 42,275 restricted stock units vested and converted into common stock. On February 2, 2026, he sold 37,771 shares of common stock at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-established automatic sell-to-cover instruction, and continued to hold 116,753 shares directly afterward.
Solid Biosciences Chief Technology Officer Paul Herzich reported several equity award events and a related share sale. On January 29, 2026, 54,925 performance stock units vested and converted one-for-one into common stock after a performance milestone was certified as achieved.
On the same date, he received an option to buy 170,000 shares at an exercise price of $6.60 per share, vesting over four years, and was granted 85,000 restricted stock units, also vesting over four years. On January 31, 2026, 24,675 RSUs from a 2025 grant vested and converted into common shares.
On February 2, 2026, Herzich sold 26,250 common shares at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting, under a durable automatic sell-to-cover instruction, and not as a discretionary trade. After these transactions, he directly owned 79,972 common shares.
Solid Biosciences director Ilan Ganot reported several equity compensation events and updated holdings. On January 29, 2026, an entity associated with his wife received an employee stock option for 70,900 shares of common stock at an exercise price of $6.6 per share, vesting over four years. On the same date, his wife was also granted 35,450 restricted stock units (RSUs), which vest in four equal annual installments.
On January 31, 2026, 15,000 RSUs associated with his wife were settled into 15,000 shares of common stock, increasing her indirect common stock holdings to 32,476 shares and RSU holdings to 45,000 units. Separately, Ganot directly and jointly holds 99,297 shares of common stock and an additional 19,394 shares are held in the Ilan Ganot 2017 Irrevocable Trust.
SLDB insider Jessie Harahan filed a Form 144 indicating an intent to sell up to 26,535 shares of common stock through E*TRADE Financial on the NASDAQ, with an approximate aggregate market value of $170,803.14.
The shares were acquired on 02/02/2026 via settlement of performance shares from the issuer as compensation. The filing notes 82,561,235 shares of common stock outstanding and discloses a prior sale over the past three months of 4,483 shares for gross proceeds of $22,908.13.
A holder of SLDB common stock has filed a notice of proposed sales under Rule 144. The filing covers 28,335 shares of common stock, to be sold through E*TRADE Financial Corporation on 02/02/2026 on the NASDAQ, with an aggregate market value of $182,389.56. These shares were acquired on the same date through settlement of performance share awards as compensation from the issuer. The filing reports that 82,561,235 shares of this class were outstanding, and indicates no other sales by this holder in the past three months.
Kevin Tan has filed a notice to sell SLDB common stock under Rule 144. The planned sale covers 26,837 shares of common stock through E*TRADE Financial, with an aggregate market value of $172,747.09, to be sold on or about February 2, 2026 on NASDAQ.
These shares were acquired on February 2, 2026 via settlement of performance shares as compensation from the issuer. In the previous three months, Kevin Tan also sold 5,704 shares of common stock on January 13, 2026, generating gross proceeds of $30,060.08. Shares outstanding were 82,561,235 at the time listed.